Now is the time for the biotechnology sector to ask for big changes to the FDA, NIH, reimbursement, intellectual property and ...

California investment firm Vivo Capital has secured $740 million in commitments to be aimed at preclinical- and ...

The Swiss Biotech Report 2025 has indicated that R&D investment in Switzerland increased in 2024, compared to 2023.

The firm, a prolific backer of drug startups, will use the cash to back companies working on therapeutics, medical devices ...

Set against a backdrop of barren biotech investment, Vivo Capital has secured $740m to back preclinical and clinical-stage ...

With long development timelines and high burn rates, biotech companies must navigate capital markets with precision.

The companies Biohaven, MoonLake Immunotherapeutics, and AIRNA bagged the biggest biotech funding rounds overall in April ...

These preclinical candidates integrate the PRO-XTEN™ masking technology with novel TCEs discovered and engineered using Vir Biotechnology’s antibody discovery platform and the Company’s ...

REITs are outperforming tech stocks in 2023. Learn about the shifting trends and potential investment opportunities. Read for ...

There has been a well-publicised boom in biotech investment during the pandemic, and the UK is no exception, with a record £1 billion raised in the third quarter. Latest figures from the ...

If you can find a solid long-term investment, you can hold that asset. If not, you can flip the stock at any time for a profit. Investors have seriously recognized biotechnology as a distinct ...